CONTE, Pierfranco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 49.880
AS - Asia 18.830
EU - Europa 18.425
SA - Sud America 2.857
Continente sconosciuto - Info sul continente non disponibili 391
AF - Africa 388
OC - Oceania 46
Totale 90.817
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 48.882
GB - Regno Unito 5.664
SG - Singapore 5.432
CN - Cina 5.181
IT - Italia 4.335
HK - Hong Kong 2.294
BR - Brasile 2.176
VN - Vietnam 1.752
SE - Svezia 1.511
DE - Germania 1.314
BD - Bangladesh 1.228
UA - Ucraina 1.123
FI - Finlandia 1.100
IE - Irlanda 931
TR - Turchia 769
RU - Federazione Russa 657
FR - Francia 636
CA - Canada 483
KR - Corea 463
IN - India 427
BG - Bulgaria 397
ID - Indonesia 246
AR - Argentina 214
MX - Messico 174
JP - Giappone 144
IQ - Iraq 139
NL - Olanda 129
EC - Ecuador 103
CO - Colombia 102
ZA - Sudafrica 97
PL - Polonia 96
AE - Emirati Arabi Uniti 91
ES - Italia 90
PK - Pakistan 83
BE - Belgio 80
VE - Venezuela 77
PH - Filippine 65
CR - Costa Rica 64
JM - Giamaica 63
MY - Malesia 63
CL - Cile 61
SA - Arabia Saudita 55
UZ - Uzbekistan 54
PY - Paraguay 49
MA - Marocco 47
AU - Australia 44
LT - Lituania 44
HN - Honduras 43
EG - Egitto 38
NP - Nepal 37
CZ - Repubblica Ceca 36
KE - Kenya 36
AT - Austria 34
JO - Giordania 34
TH - Thailandia 32
AL - Albania 29
TN - Tunisia 29
IR - Iran 27
UY - Uruguay 26
AZ - Azerbaigian 25
ET - Etiopia 25
HU - Ungheria 25
TT - Trinidad e Tobago 24
TW - Taiwan 24
DZ - Algeria 23
PE - Perù 23
RO - Romania 23
BO - Bolivia 22
RS - Serbia 22
DO - Repubblica Dominicana 21
IL - Israele 21
CH - Svizzera 20
NI - Nicaragua 20
GT - Guatemala 19
PT - Portogallo 18
KZ - Kazakistan 17
LB - Libano 17
OM - Oman 17
GR - Grecia 16
NG - Nigeria 16
SV - El Salvador 16
PR - Porto Rico 15
BB - Barbados 14
SN - Senegal 14
EE - Estonia 13
SI - Slovenia 13
SK - Slovacchia (Repubblica Slovacca) 12
BH - Bahrain 11
PA - Panama 11
CI - Costa d'Avorio 10
EU - Europa 10
KG - Kirghizistan 10
QA - Qatar 10
SY - Repubblica araba siriana 10
AM - Armenia 9
BW - Botswana 9
DK - Danimarca 9
MD - Moldavia 9
PS - Palestinian Territory 9
AO - Angola 7
Totale 90.289
Salva come PNG Salva come JPEG
Città #
Ashburn 5.665
Fairfield 4.174
Southend 3.802
Singapore 3.516
Santa Clara 3.144
Woodbridge 3.075
Houston 2.638
Jacksonville 2.299
Hong Kong 2.261
Chandler 2.038
Ann Arbor 1.737
San Jose 1.660
Dearborn 1.572
Seattle 1.558
Wilmington 1.530
Hefei 1.526
Cambridge 1.378
Council Bluffs 1.331
Beijing 1.032
London 944
Dublin 925
Nyköping 827
Los Angeles 795
Helsinki 711
Chicago 657
The Dalles 651
Modena 644
New York 605
Ho Chi Minh City 587
Milan 510
Princeton 444
San Diego 441
Seoul 430
Hanoi 396
Sofia 381
Eugene 379
Izmir 364
Columbus 336
Lauterbourg 319
Buffalo 309
São Paulo 240
Salt Lake City 229
Rome 221
Dallas 219
Shanghai 214
Des Moines 208
Moscow 203
Boardman 188
Phoenix 172
Jakarta 150
Falls Church 143
Munich 141
Frankfurt am Main 122
Tampa 118
Elk Grove Village 117
Bologna 109
Toronto 108
Atlanta 104
Naples 104
Tokyo 103
Norwalk 94
Orem 91
Guangzhou 85
Denver 81
Da Nang 80
Turin 80
Florence 74
North Bergen 73
Brussels 72
Haiphong 71
Brooklyn 69
Lancaster 66
Miano 66
Warsaw 65
Mexico City 63
Chennai 62
Redwood City 60
Montreal 57
Philadelphia 57
Rio de Janeiro 57
Dong Ket 54
Sterling 54
Fremont 53
Belo Horizonte 51
Nanjing 51
Newark 51
Porto Alegre 51
Brasília 50
Boston 49
Bremen 49
Kunming 49
Miami 49
Verona 48
Bari 47
Norfolk 47
Redondo Beach 47
Falkenstein 45
San José 45
Tashkent 45
Baghdad 41
Totale 63.203
Salva come PNG Salva come JPEG
Nome #
VALORE PROGNOSTICO E PREDITTIVO DI p53 NEL CARCINOMA MAMMARIO TRATTATO CON CHEMIOTERAPIA NEOADIUVANTE 1.187
ShortHER: TRATTAMENTO ADIUVANTE CON HERCEPTIN PER 3 MESI VERSO 12 MESI, IN ASSOCIAZIONE CON DUE DIFFERENTI REGIMI DI CHEMIOTERAPIA, NELLE PAZIENTI CON CARCINOMA MAMMARIO HER2 POSITIVO 512
Rigenerand srl - Spin off Università di Modena e Reggio Emilia 473
A Dose-finding and Biomarker Evaluation Phase Ib Study of Everolimus in Association With 5-Fluorouracil and Pelvic Radiotherapy as Neoadjuvant Treatment of Locally Advanced Rectal Cancer (E-LARC Study) 464
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study 459
Phase I study of intraperitoneal MHC unrestricted adoptive cell therapy with TALL-104 cells in patients with peritoneal carcinosis 454
Soluble TRAIL Armed Human MSC As Gene Therapy For Pancreatic Cancer 448
Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management 447
Magnetic Resonance Imaging and Ultrasonography in Predicting Infiltrating Residual Disease after Preoperative Chemotherapy in Stage II-III Breast Cancer 441
MSC-delivered soluble TRAIl and paclitaxel as novel combinatory treatment for pancreatic adenocarcinoma 439
9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study. 436
GMP-manufactured density gradient media for optimized mesenchymal stromal/stem cell isolation and expansion. 436
Prognostic value of Dworak grade of regression (GR) in patients with rectal carcinoma treated with preoperative radiochemotherapy 425
A novel anti-GD2/4-1BB chimeric antigen receptor triggers neuroblastoma cell killing 415
MSC and Tumors: Homing, Differentiation and Secretion Influence The Therapeutic Potentials 412
Phase II, randomized trial of preoperative epirubicin-paclitaxel +/- gefitinib with biomarker evaluation in operable breast cancer. 410
Cytogenetic abnormalities and clinical features in a patient cohort affected by three or more synchronous or metachronous primitive malignancies. 410
MODULAZIONE DELL’ESPRESSIONE DI BIOMARCATORI E PROGNOSI IN PAZIENTI AFFETTE DA CARCINOMA MAMMARIO OPERABILE SOTTOPOSTE A CHEMIOTERAPIA PREOPERATORIA 408
Isolation, characterization, and transduction of endometrial decidual tissue multipotent mesenchymal stromal/stem cells from menstrual blood 407
A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy 406
Predictors of human epidermal growth factor receptor 2 fluorescence in-situ hybridisation amplification in immunohistochemistry score 2+ infiltrating breast cancer: a single institution analysis. 403
Neoadjuvant treatment with Single – Agent Cetuximab Followed by 5-Fu, Cetuximab, and Pelvic Radiotherapy: A Phase II Study in Locally Advanced Rectal Cancer. 403
SOLUBLE TRAIL-ARMED HUMAN AD-MSC AS NOVEL CELL THERAPY APPROACH FOR PANCREATIC DUCTAL ADENOCARCINOMA 401
Letrozole Versus Letrozole Plus Lapatinib (GW572016) in Hormone-Sensitive, HER2-Negative Operable Breast Cancer: A Double-Blind, Randomized Phase II Study with Biomarker Evaluation (EGF109077-LAP107692/LETLOB) 394
Le Cellule Staminali Mesenchimali: Aspetti Biologici ed Approcci Terapeutici 394
Mutational Profile of Metastatic Breast Cancer Tissue in Patients Treated with Exemestane Plus Everolimus 381
Mesenchymal progenitors aging highlights a mir-196 switch targeting HOXB7 as master regulator of proliferation and osteogenesis 378
Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer. 378
Epidermal growth factor receptor gene copy number, K-ras mutation and pathological response to preoperative cetuximab, 5-FU and radiation therapy in locally advanced rectal cancer.. 374
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial . 374
Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer 367
Animal serum-free culture conditions for isolation and expansion of multipotent mesenchymal stromal cells from human BM 364
Predictive and prognostic role of p53 according to tumor phenotype in breast cancer patients treated with preoperative chemotherapy: a single-institution analysis 363
Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer 358
3* Final analysis of the phase III multicentric Italian study Short-HER: 9 weeks vs 1 year adjuvant trastuzumab for HER2+ early breast cancer 356
Mesenchymal progenitors expressing TRAIL induce apoptosis in sarcomas 356
Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma 355
Clinical and molecular predictors of long-term response in HER2 positive metastatic breast cancer patients. 351
Proteasome inhibitors sensitize colon carcinoma cells to TRAIL-induced apoptosis via enhanced release of Smac/DIABLO from the mitochondria 349
Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial 348
FOLFOX6 and bevacizumab in non-optimally resectable liver metastases from colorectal cancer 347
CHER LOB Trial: Preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2-positive operable breast cancer--Safety report as per Independent Data Monitoring Committee (IDMC) and preliminary activity data 346
Achievements and unmet needs in the management of advanced ovarian cancer 345
A prognostic model based on nodal status and Ki 67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy 345
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. 345
Prognostic and Predictive Value of Baseline and Posttreatment Molecular Marker Expression in Locally Advanced Rectal Cancer Treated With Neoadjuvant Chemoradiotherapy 344
Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients 342
Ki67 as a Predictor of Response and Long Term Survival in Hormone Receptor Positive/HER2 Negative Breast Cancer Patients Treated with Preoperative Chemotherapy 337
Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single Institution analysis 337
METHOD FOR PRODUCTION OF ANTI-TUMOR TRAIL PROTEIN 335
Preoperative chemotherapy plus lapatinib or trastuzumab or both in Her2 positive operable breast cancer. EGF109085-LAP106988/CHERLOB Trial. 331
Double-blind, placebo-controlled, multicentric randomized phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal HER2-negative, hormone receptor-positive operable breast cancer 330
Biomarker expression and survival after primary chemotherapy for breast cancer. 329
Rare breast cancer subtypes: Histological, molecular, and clinical peculiarities 327
Restoration and reversible expansion of the osteoblastic hematopoietic stem cell niche after marrow radioablation 327
Immune characterization of breast cancer metastases: prognostic implications. 326
Final results of a phase II randomized trial of neoadjuvant anthracycline-taxane chemotherapy plus lapatinib, trastuzumab, or both in HER2-positive breast cancer (CHER-LOB trial). 325
5-Fluorouracil administered as a 48-hour chronomodulated infusion in combination with leucovorin and cisplatin: A randomized phase II study in metastatic colorectal cancer 323
9 Weeks vs 1 Year Adjuvant Trastuzumab in Combination with Chemotherapy: Preliminary Cardiac Safety Data of the Phase III Multicentric Italian Study Short-HER. 323
Laparoscopic approach of gastric gastrointestinal stromal tumors (GISTs): Is it still a courageous choice? Report of two cases 321
Bevacizumab and osteonecrosis of the jaw: Incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer 318
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation 318
A dose-finding study of ifosfamide by three-day continuous infusion in pretreated, advanced breast cancer patients. 317
Magnetic resonance imaging and ultrasonography in predicting pathologic extent after preoperative chemotherapy in stage II-III breast cancer 312
Primary adrenal gland carcinosarcoma associated with metastatic rectal cancer: a hitherto unreported collision tumor 307
Donor Cell-Derived Osteopoiesis Originates from a Self-Renewing Stem Cell with a Limited Regenerative Contribution after Transplantation 307
The curability of breast cancer and the treatment of advanced disease 306
Incidence and clinical impact of sterilized disease and minimal residual disease after preoperative radiochemotherapy for rectal cancer 305
A phase I-II study of oral doxifluridine plus radiotherapy in radiosensitive tumors of the pelvic region. 305
Q-TWiST analysis of ixabepilone in combination with capecitabine on quality of life in patients with metastatic breast cancer 305
Change in HER2 Status in HER2 Positive Operable Breast Cancer Patients Treated with Neoadjuvant Chemotherapy with or without Anti-HER2 Therapy: Analysis of Two Consecutive Cohorts 305
Prognostic value of "Dworak" tumor regression grade (TRG) after pre-operative chemo-radiotherapy in rectal cancer (RC) 303
Preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2 positive operable breast cancer: results of the randomized phase II CHER-LOB study 297
PREVALENCE OF NODE NEGATIVE AND SMALL SIZE TUMORS IN A NATIONAL, RANDOMISED, PHASE III ADJUVANT TRIAL IN HER2 + EARLY BREAST CANCER (SHORT-HER STUDY) 296
Gastrointestinal stromal tumor and other primary metachronous and synchronous neoplasms as a suspicious criterion for syndromic setting 294
Significance of lymph node sampling in epithelial carcinoma of the ovary. 292
Preliminary safety data of preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2-positive operable breast cancer 290
PROLIFERATION AND APOPTOSIS BEFORE AND AFTER PRIMARY SYSTEMIC THERAPY FOR OPERABLE BREAST CANCER 290
35. PREDICTORS OF HER2 FISH POSITIVITY IN PRIMARY BREAST CANCER DIAGNOSIS SCORED 2+ WITH IHC: RESULTS OF A SINGLE INSTITUTION ANALYSIS 290
Prognostic role of EGFR gene copy number and KRAS mutation in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy. 287
Evolving nonendocrine therapeutic options for metastatic breast cancer: how adjuvant chemotherapy influences treatment. 286
Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. 285
Cardiotoxicity of Epirubicin/Paclitaxel Containing Regimens: Role of Cardiac Risk Factors 284
Intraperitoneal versus Intravenous Cisplatin in Combination with Intravenous Cyclophosphamide and Epidoxorubicin in Optimally Cytoreduced Advanced Epithelial Ovarian Cancer: A randomized trial of the Gruppo Oncologico Nord Ovest. 284
Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of After-6 protocol 1 284
Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer. 282
Varicella zoster virus reactivation in patients with breast cancer and multiple myeloma after autologous stem cell transplantation 280
Trans-CHER-Lob: A Biomarker Analysis of the Randomized Phase II Study of Neoadjuvant Chemotherapy Plus Trastuzumab, Lapatinib or Combined Trastuzumab and Lapatinib in HER2 Positive Operable Breast Cancer. 279
Paclitaxel and vinorelbine in anthracycline pretreated breast cancer: a phase II study. 277
Erratum to: Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2− breast cancer: results from two prospective trials (Breast Cancer Research and Treatment, (2017), 163, 2, (295-302), 10.1007/s10549-017-4191-y) 276
Randomized phase III trials of adjuvant FAMTX or FEMTX compared with surgery alone in resected gastric cancer. A combined analysis of the EORTC GI Group and the ICCG 275
Device for cell culture 274
Biomarkers predicting clinical benefit: fact or fiction? 272
P53 EXPRESSION IS A SIGNIFICANT PREDICTOR OF RESPONSE AND PROGNOSIS IN STAGE II-III BREAST CANCER PATIENTS TREATED WITH PREOPERATIVE CHEMOTHERAPY 272
Analysis of Bevacizumab (Bev) Therapy, Bisphosphonate Use and Osteonecrosis of the Jaw (ONJ) in >1900 Patients Treated in Two Randomized, Controlled Trials 271
Use of Ki-67 in residual disease following preoperative chemotherapy to predict of recurrence and death in breast cancer patients. 270
A phase II study with danazol in metastatic breast cancer. 269
Anthracycline-based preoperative chemotherapy plus lapatinib and trastuzumab or both in HER2-positive breast cancer: Preliminary cardiac safety report of the CHER LOB trial. 268
41. HER2+ EARLY BREAST CANCER: DO WE HAVE ALL THE NECESSARY ANSWERS? 268
Discordant HER2 Total and HER2 Homodimer Levels by HERmark Analysis in Matched Primary and Metastatic Breast Cancer FFPE Specimens. 266
Totale 35.187
Salva come PNG Salva come JPEG
Categoria #
all - tutte 340.163
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 340.163
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20224.417 0 0 0 382 147 259 445 325 648 469 962 780
2022/20236.351 741 573 316 510 659 906 77 541 1.521 83 257 167
2023/20243.774 182 248 204 229 705 349 393 705 125 114 163 357
2024/202511.504 362 159 183 872 2.139 1.812 493 761 1.480 780 1.022 1.441
2025/202625.948 1.329 1.003 2.221 3.016 3.369 2.034 2.813 1.440 2.168 2.625 2.172 1.758
2026/20278.292 1.011 1.759 2.615 2.907 0 0 0 0 0 0 0 0
Totale 90.817